Evidence map›Paper›PMID 42189126›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Genome-Wide CRISPR Screen Identifies a microRNA Orchestrating Pleiotropic Resistance to Targeted Therapy and T Cell Immunity in Melanoma.

Zhao Wang, Haotian Liu, Xueqi Wang, Jianjin Teng, Zihan Zheng, Jingya Zhang, Wanyi Xiao, Qian Liang, Jiaxin Li, Xiaomeng Jia and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Zhao WangDepartment of Pharmacology, State Key Laboratory of Experimental Hematology, The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, Tianjin Key Laboratory of Inflammation Biology, School of Basic Medical Sciences, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China.
Haotian LiuDepartment of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, National Clinical Research Center for Cancer, Tianjin, China.
Xueqi WangDepartment of Bioinformatics, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.
Jianjin TengDepartment of Bioinformatics, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.
Zihan ZhengDepartment of Pharmacology, State Key Laboratory of Experimental Hematology, The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, Tianjin Key Laboratory of Inflammation Biology, School of Basic Medical Sciences, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China.
Jingya ZhangGuangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.
Wanyi XiaoDepartment of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, National Clinical Research Center for Cancer, Tianjin, China.
Qian LiangDepartment of Pharmacology, State Key Laboratory of Experimental Hematology, The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, Tianjin Key Laboratory of Inflammation Biology, School of Basic Medical Sciences, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China.
Jiaxin LiOujiang Laboratory, Wenzhou Medical University, Wenzhou, China.
Xiaomeng JiaOujiang Laboratory, Wenzhou Medical University, Wenzhou, China.
Xin FengOujiang Laboratory, Wenzhou Medical University, Wenzhou, China.
Hongzhang CuiOujiang Laboratory, Wenzhou Medical University, Wenzhou, China.
Menghan LuoDepartment of Bioinformatics, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.
Tielong YangDepartment of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, National Clinical Research Center for Cancer, Tianjin, China.
Liuxing WuDepartment of Bioinformatics, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.
Ke ZhaoDepartment of Pharmacology, State Key Laboratory of Experimental Hematology, The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, Tianjin Key Laboratory of Inflammation Biology, School of Basic Medical Sciences, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China.
Weilong YangGuangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.
Mulin Jun LiDepartment of Pharmacology, State Key Laboratory of Experimental Hematology, The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, Tianjin Key Laboratory of Inflammation Biology, School of Basic Medical Sciences, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China.ORCID https://orcid.org/0000-0003-3598-3679
Dandan HuangDepartment of Pharmacology, State Key Laboratory of Experimental Hematology, The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, Tianjin Key Laboratory of Inflammation Biology, School of Basic Medical Sciences, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China.
Jilong YangDepartment of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, National Clinical Research Center for Cancer, Tianjin, China.

Funding

Cancer Biobank of Tianjin Medical University Cancer Institute and HospitalMajor Project of State Key Laboratory of Experimental Hematology in 2025Major Project of the National Key Laboratory of Drug Developability Evaluation and Systematic Transformation in 2025National Human Genetic Resources Sharing Service Platform 2005DKA21300National Key Laboratory Major Special Project of Tianjin Science and Technology Plan Project 25ZXZSSS00910National Key Research and Development program of China 016YFC1201703National Key Research and Development Program of China 2024YFC2707700National Natural Science Foundation of China 32000640National Natural Science Foundation of China 32470671National Natural Science Foundation of China 82422038National Natural Science Foundation of China 82473477Natural Science Foundation of Tianjin 24JCZDJC00480Natural Science Foundation of Zhejiang LZYQ25H090001Oujiang Laboratory Research Launch Project OJQD2024001Tianjin Medical University Cancer Hospital 'Clinical-Basic' Co-PI Project 20250204
6 · The paper itself

Abstract

Acquired resistance to both targeted therapies and immunotherapies in cancer presents major clinical challenges, yet the molecular mechanisms underlying cross-resistance remain poorly understood. We hypothesized that loss of specific microRNAs (miRNAs) could potentiate melanoma resistance to both targeted drugs and CD8

Indexed as

CD8-Positive T-LymphocytesDrug Resistance, NeoplasmMelanomaMicroRNAsAnimalsCell Line, TumorClustered Regularly Interspaced Short Palindromic RepeatsCRISPR-Cas SystemsHumansMiceMicroRNAsCRISPR screenhippo signalingmelanomamiR‐18atargeted therapy resistanceT cell immunityTHBS1–CD47 axis

Identifiers

PMID42189126
PMCPMC13335869

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.